Homology Medicines

Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date. The payment date for such distribution is expected to be March 27, 2024 (three business days after the expected closing of the merger on March 22, 2024). Each CVR represents the non-transferable contractual right to receive certain contingent payments upon the occurrence of certain events within agreed time periods as provided in the merger agreement and agreement governing the CVRs.

Homology Medicines Declares Distribution to Common Stockholders

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequa.

HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX

NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

HOMOLOGY MEDICINES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX

Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement

Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Homology Medicines, Inc. (NASDAQ: FIXX) and Q32 Bio Inc. is fair to Homology shareholders. Upon completion of the proposed transaction, Homology shareholders are expected to own approximately 25% of the combined company. Halper Sadeh encourages Homology shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763.

FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders

--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders-- --Q32 Bio has re-acquired worldwide development and commercial rights to bempikibart, an anti-IL-7Rα antibody inhibiting IL-7 and TSLP-mediated signaling, and remains on-track to report multiple topline Phase 2 results in 2H'24 -- --Concurrent $42 million private placement investment with new and existing investors supports clinical development through multiple milestones, including key Phase 2 readouts for bempikibart, initial ADX-097  proof-of-concept data by year-end 2024 and ADX-097 topline results in 2H'25 -- --Combined company's cash balance expected to be approximately $ 115 million at close, providing cash runway to mid-2026-- WALTHAM, Mass. and BEDFORD, Mass.

Q32 Bio and Homology Medicines Announce Merger Agreement

- Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines,  including HMI-103 -

Homology Medicines Reports Third Quarter 2023 Financial Results

PHILADELPHIA , Aug. 16, 2023 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) on behalf of the Company's long-term investors.  Recently an amended securities fraud complaint was filed against Homology on behalf of investors who purchased shares of the Company's stock between March 12, 2020 and February 18, 2022.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (NASDAQ: FIXX) and Encourages Long-Term Investors to Contact the Firm - FIXX

Akari Therapeutics

Ardelyx

Carmell Therapeutics Corp

Invitae

Rigetti Computing

Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.

Best Penny Stocks To Buy? 6 To Watch Before Next Week

There's something special about penny stocks. Even when the stock market is down, like it is today, you're likely to find at least a handful exploding higher.

Penny Stocks To Buy? 3 To Watch While The Stock Market Is Down

Participant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold (

Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU

- New Preclinical Data Demonstrated Ability to Re-Dose with AAVHSCs Across Viral Clades, Potentially Expanding Possibilities of Genetic Medicine Programs in the Future -

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting

Homology Medicines (FIXX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.20 per share a year ago.

Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates

- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial  Mid-Year 2023 -

Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights

-   First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -

Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting

BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the preclinical data that supported initiation of the Company's Phase 1 pheEDIT gene editing trial for phenylketonuria (PKU) and the Phase 1 juMPStart gene therapy trial for Hunter syndrome (MPS II). Additionally, the presentations feature trial design, including the targeted immunosuppression regimen incorporated in both studies. The pheEDIT-focused presentation also includes preclinical potency data with HMI-103, the nuclease-free, in vivo, gene editing candidate for PKU.

Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting

Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates

- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year  with First Participant Dosed and Others in Screening -

Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr. Jordan held the role of Senior Vice President, Head of Clinical Development and Operations, at Homology, and she has been instrumental in advancing Homology's gene editing and gene therapy clinical programs. Under her leadership, Homology is conducting the pheEDIT trial for phenylketonuria (PKU) evaluating gene editing candidate HMI-103 designed to maximize PAH enzyme through both genome integration and episomal expression, and the juMPStart trial for Hunter syndrome (MPS II) evaluating systemic gene therapy candidate HMI-203 designed to address peripheral and central nervous system components of the disease. Initial clinical data from pheEDIT is expected mid-year and juMPStart initial data is anticipated in the second half of 2023.

Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer

BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET.

Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

Preclinical Studies Demonstrated a Targeted Immunosuppression Approach Led to Reduced Immune Response to AAVHSC Administration and Improved Gene Expression

Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting

Strong Cash Position with Runway into Fourth Quarter 2024

Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs

ElectroCore Inc

Grab Holdings Ltd

iQIYI

Porch Group

Analysts say these are penny stocks to buy but do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050%

Homology Medicines (FIXX) delivered earnings and revenue surprises of -25.53% and 23.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates

- On Track for Updates on pheEDIT and juMPStart Programs by Year-End -

News for Homology Medicines Stock (FIXX)